Lantheus Holdings, Inc. to Post Q1 2024 Earnings of $1.47 Per Share, Leerink Partnrs Forecasts (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Investment analysts at Leerink Partnrs lowered their Q1 2024 earnings per share estimates for Lantheus in a note issued to investors on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now anticipates that the medical equipment provider will post earnings per share of $1.47 for the quarter, down from their prior forecast of $1.48. The consensus estimate for Lantheus’ current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Lantheus’ Q2 2024 earnings at $1.49 EPS, FY2024 earnings at $5.92 EPS and FY2025 earnings at $5.49 EPS.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million.

LNTH has been the topic of several other reports. JMP Securities reiterated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Truist Financial reissued a “buy” rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. B. Riley boosted their target price on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday. Finally, StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $63.81 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. Lantheus has a one year low of $50.20 and a one year high of $100.85. The company has a market cap of $4.37 billion, a price-to-earnings ratio of 13.75 and a beta of 0.53. The firm has a 50 day simple moving average of $60.81 and a 200 day simple moving average of $62.97.

Institutional Trading of Lantheus

A number of hedge funds have recently made changes to their positions in the stock. Tucker Asset Management LLC boosted its holdings in shares of Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares in the last quarter. Principal Securities Inc. bought a new stake in shares of Lantheus in the 4th quarter worth approximately $28,000. First Horizon Advisors Inc. boosted its stake in shares of Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares in the last quarter. West Tower Group LLC grew its holdings in shares of Lantheus by 534.1% during the 4th quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 438 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Lantheus by 60.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 160 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Transactions at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 94,545 shares of company stock valued at $6,169,936. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.